MedTrace Logo

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

NCT00783549 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2017-07-07

No results posted yet for this study

Summary

This study is the first study in humans to assess the safety and tolerability of various doses of GSK1292263 alone, and taken with sitigliptan.

Conditions

  • Dyslipidaemias

Interventions

DRUG

an undetermined dose of GSK1292263

GSK investigational product or placebo

DRUG

ascending dose of GSK1292263

Ascending dose based on target exposures or placebo

DRUG

ascending dose of GSK1292263

An ascending dose based on target exposure

DRUG

ascending dose of GSK1292263

An ascending dose based on target exposures.

DRUG

ascending dose of GSK1292263

An ascending dose based on target exposure

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-04
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00783549 on ClinicalTrials.gov